New approaches for drug-based kidney disease therapy

July 10, 2018, CORDIS
New approaches for drug-based kidney disease therapy
Credit: crystal light, Shutterstock

Whilst most scientific attention in the fight against kidney disease is currently focused on stem cells, the EVESTIMINJURY project has been investigating the extracellular vesicles being released by these stem cells. The resulting treatment could provide an excellent alternative to cell-based therapy.

A few years ago, scientists found out just how amazing our kidneys actually were: contrary to popular belief, they had the capacity to regenerate and repair themselves throughout life. This regeneration process, however, has its limitations. In the face of the absence of symptoms during the early stages of and a frequent lack of follow-up, it hasn't been enough to prevent many patients across Europe from permanently losing some functions or even dying from chronic and acute kidney disease.

It's easy to understand why this context would make stem look like the holy grail. Clinical trials for several types of stem cells are ongoing and show much promise. But according to the five organisations responsible for the EVENTEMINJURY project, the real potential doesn't lie in the stem cells themselves, but rather in the extracellular vesicles (EVs) released by these stem cells.

"EVs have been shown to mimic the biological activity of the cells by transferring stem cell-derived molecules (proteins, biological active lipids and nucleic acids) able to activate endogenous processes to the injured tissue. In patients with acute and chronic kidney diseases, EVs may be an alternative to cell-based therapy, with the advantage that EVs derived from stem cells are not immunogenic, are bio-compatible and can be administered as a drug," explains Professor Fiorella Altruda, who coordinated the project on behalf of Bioindustry Park 'Silvano Fumero'.

This potential had already been investigated prior to the project, with a focus on . The studies were a source of optimism, but what really caught the eye of Prof. Altruda and her colleagues was the lack of information available on the molecular mechanisms at play.

The EVESTIMINJURY project was meant to fill this gap. It provides mechanistic information on EV regenerative mechanisms and, more specifically, the potential role of EVs in chronic kidney injury by studying the ability of stem cell-derived EVs to inhibit fibrosis.

Different subsets of EVs were characterized with regards to their anti-fibrotic properties. The project consortium used three different separation techniques for that, to isolate EVs from bone marrow (MSC) – the most widely used cells for the treatment of kidney diseases – and hepatic liver stem cells (HLSC).

"The first isolation technique was based on differential ultracentrifugation," explains Prof. Altruda. "It allowed for the separation of two main fractions at 10K and 100K g. Then, the second protocol was based on the selection of different EV sub-populations using the flotation iodixanol gradient separation method, which enabled the selection of 12 fractions containing different subsets of EVs. Finally, the third isolation technique – based on size exclusion chromatography – enabled the separation of a pure exosomal fraction from other EV subsets and proteins. EV dimension and profile were analyzed using Nanosight LM10 from project partner NanoSight Ltd, and EVs were also characterized by western blot analysis, electron microscopy and cytofluorimetric analysis."

The results demonstrate how fractions differ in terms of molecular components as well as in vitro/in vivo regenerative potential. The total EV fraction was shown to be the most effective in inducing tubular epithelial regeneration and anti-fibrotic effect both in vitro and in vivo. In particular, pre-clinical studies confirmed that stem cell-derived EVs display a significant pro-regenerative effect on the kidney.

Buoyed by this success, the consortium will now focus on the up-scaling of EV production from as well as a GMP protocol for potential clinical use. All knowledge gathered throughout the project will be made available to other organisations and universities.

"Of course, using this knowledge to start curing patients will require more time. Further studies are needed to investigate bio-distribution, bio-availability, pharmaco-dynamics, bio-safety, as well as how and when to administer the drug. Moreover, the criteria for the characterisation of a product for human use are still to be defined and approved by regulatory agencies," Prof. Altruda says.

Explore further: Kidney cells from amniotic fluid obtained from cesarean section at delivery

Related Stories

Kidney cells from amniotic fluid obtained from cesarean section at delivery

May 8, 2018
Amniotic fluid can be routinely obtained without harming the mother or the fetus. Researchers have previously demonstrated that amniotic fluid contains mesenchymal stem cells with great differentiation and regenerative potential. ...

Researchers move one step closer towards functioning kidney tissue from stem cells

March 2, 2018
Researchers from the Murdoch Children's Research Institute (MCRI), University of Melbourne and Leiden University Medical Centre (LUMC) in The Netherlands have made an important step towards making human kidneys from stem ...

Mesenchymal stem cell therapy: Holding promise for feline inflammatory diseases

March 13, 2018
Stem cell therapy is acknowledged as having great potential for the treatment of a variety of diseases in both people and animals. The use of bone marrow-derived stem cells is well established in the treatment of human cancer ...

Body's fatty folds may help fight kidney failure

March 21, 2014
A fatty fold of tissue within the abdomen that is a rich source of stem cells can help heal diseased kidneys when fused to the organs, according to a study conducted in rats. The findings, which appear in an upcoming issue ...

Combining stem-cell therapy with anti-scarring agent may heal injured kidneys

March 16, 2015
Researchers have made a discovery that could see patients with kidney disease no longer having to resort to dialysis or kidney transplants.

Recommended for you

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Exercise-induced hormone irisin triggers bone remodeling in mice

December 13, 2018
Exercise has been touted to build bone mass, but exactly how it actually accomplishes this is a matter of debate. Now, researchers show that an exercise-induced hormone activates cells that are critical for bone remodeling ...

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Law professor suggests a way to validate and integrate deep learning medical systems

December 13, 2018
University of Michigan professor W. Nicholson Price, who also has affiliations with Harvard Law School and the University of Copenhagen Faculty of Law, suggests in a Focus piece published in Science Translational Medicine, ...

Pain: Perception and motor impulses arise in brain independently of one another

December 13, 2018
Pain is a negative sensation that we want to get rid of as soon as possible. In order to protect our bodies, we react by withdrawing the hand from heat, for example. This action is usually understood as the consequence of ...

Researchers give new insight to muscular dystrophy patients

December 13, 2018
New research by University of Minnesota scientists has revealed the three-dimensional structure of the DUX4 protein, which is responsible for the disease, facioscapulohumeral muscular dystrophy (FSHD). Unlike the majority ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.